Can Proton MR Spectroscopic and Perfusion Imaging Differentiate Between Neoplastic and Nonneoplastic Brain Lesions in Adults?

References

1. ↵
   Rand SD, Prost R, Haughton V, et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997;18:1695–704

   Abstract
2. ↵
   Burger PC. Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin Oncol 1986;13:16–26

   PubMed
3. ↵
   Al-Okaili RN, Krejza J, Woo JH, et al. Intraaxial brain masses: MR imaging-based diagnostic strategy—initial experience. Radiology 2007;243:539–50

   CrossRefPubMedWeb of Science
4. ↵
   Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593–603

   Abstract
5. Poptani H, Kaartinen J, Gupta RK, et al. Diagnostic assessment of brain tumours and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks. J Cancer Res Clin Oncol 1999;125:343–49

   CrossRefPubMed
6. ↵
   Butzen J, Prost R, Chetty V, et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000;21:1213–19

   Abstract/FREE Full Text
7. ↵
   Möller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371–81

   CrossRefPubMedWeb of Science
8. ↵
   De Stefano N, Caramanos Z, Preul MC, et al. In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging. Ann Neurol 1998;44:273–78

   CrossRefPubMedWeb of Science
9. Venkatesh SK, Gupta RK, Pal L, et al. Spectroscopic increase in choline signal is a nonspecific marker for differentiation of infective/inflammatory from neoplastic lesions of the brain. J Magn Reson Imaging 2001;14:8–15

   CrossRefPubMed
10. Vuori K, Kankaanranta L, Häkkinen AM, et al. Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology 2004;230:703–08

    PubMed
11. ↵
    Pandya HG, Wilkinson ID, Agarwal SK, et al. The nonspecific nature of proton spectroscopy in brain masses in children: a series of demyelinating lesions. Neuroradiology 2005;47:955–59

    CrossRefPubMed
12. ↵
    Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
13. ↵
    Law M, Hamburger M, Johnson G, et al. Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging. Technol Cancer Res Treat 2004;3:557–65

    Abstract/FREE Full Text
14. ↵
    Hourani R, Horská A, Albayram S, et al. Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging 2006;23:99–107

    CrossRefPubMed
15. ↵
    Duyn JH, Gillen J, Sobering G, et al. Multisection proton MR spectroscopic imaging of the brain. Radiology 1993;188:277–82

    PubMedWeb of Science
16. ↵
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839–43

    CrossRefPubMedWeb of Science
17. ↵
    Gill SS, Thomas DG, Van Bruggen N, et al. Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies. J Comput Assist Tomogr 1990;14:497–504

    PubMedWeb of Science
18. ↵
    Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223–32

    CrossRefPubMed
19. ↵
    Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323–25

    CrossRefPubMedWeb of Science
20. ↵
    Burtscher IM, Skagerberg G, Geijer B, et al. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000;21:84–93

    Abstract/FREE Full Text
21. ↵
    Nelson SJ. Multivoxel magnetic resonance spectroscopy of brain tumors. Mol Cancer Ther 2003;2:497–507

    Abstract/FREE Full Text
22. ↵
    Saraf-Lavi E, Bowen BC, Pattany PM, et al. Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels. AJNR Am J Neuroradiol 2003;24:946–51

    Abstract/FREE Full Text
23. ↵
    Londoño A, Castillo M, Armao D, et al. Unusual MR spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myo-inositol and glycine levels. AJNR Am J Neuroradiol 2003;24:942–45

    Abstract/FREE Full Text
24. ↵
    Saindane AM, Cha S, Law M, et al. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2002;23:1378–86

    Abstract/FREE Full Text
25. ↵
    Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87

    FREE Full Text
26. ↵
    Taylor JS, Langston JW, Reddick WE, et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996;36:1251–61

    CrossRefPubMed
27. ↵
    Rock JP, Hearshen D, Scarpace L, et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002;51:912–19; discussion 919–20

    CrossRefPubMedWeb of Science
28. ↵
    Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98

    Abstract/FREE Full Text
29. ↵
    Cha S, Tihan T, Crawford F, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005;26:266–73

    Abstract/FREE Full Text
30. ↵
    Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected] [published erratum appears in AJNR Am J Neuroradiol 2004;25:B1]. AJNR Am J Neuroradiol 2004;25:214–21

    Abstract/FREE Full Text
31. ↵
    Covarrubias DJ, Rosen BR, Lev MH. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004;9:528–37

    Abstract/FREE Full Text
32. ↵
    Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–09

    Abstract/FREE Full Text
33. ↵
    Cha S, Pierce S, Knopp EA, et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2001;22:1109–16

    Abstract/FREE Full Text
34. ↵
    Rabinov JD, Lee PL, Barker FG, et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002;225:871–79

    PubMedWeb of Science